IE
ENTA icon

Israel Englander’s Enanta Pharmaceuticals ENTA Stock Holding History

Israel Englander’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-190,400
Closed -$2.28M – 6110
2025
Q3 		$2.28M Buy
190,400
+140,400
+281% +$1.12M ﹤0.01% 3931
2025
Q2 		$378K Buy
+50,000
New +$301K ﹤0.01% 5072

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Israel Englander's ENTA Position: Q2 2026 in Review

Israel Englander reduced its Enanta Pharmaceuticals (ENTA) stake by 27% in Q2 2026, selling an estimated $3.2M and leaving 643,967 shares worth $9.39M. The position accounts for ﹤0.01% of the portfolio, ranked #2339.

Israel Englander first reported a position in ENTA in Q4 2013 and has held it in 44 quarters since. The position peaked at $17.5M in Q2 2017. 122 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Israel Englander held 643,967 shares of Enanta Pharmaceuticals worth $9.39M as of Q2 2026.
  • Israel Englander sold 238,130 Enanta Pharmaceuticals shares in Q2 2026, an estimated $3.2M.
  • Enanta Pharmaceuticals made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2339 holding.
  • Israel Englander first reported a position in Enanta Pharmaceuticals in Q4 2013 and has held it in 44 quarters since.
  • Israel Englander's Enanta Pharmaceuticals position peaked at $17.5M in Q2 2017.
  • 122 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.